close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

0.2748 -0.0163 (-5.60%)
Streaming Delayed Price Updated: 2:22 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 998,518
Open 0.2894
Bid (Size) 0.2739 (100)
Ask (Size) 0.2757 (100)
Prev. Close 0.2911
Today's Range 0.2680 - 0.2894
52wk Range 0.2500 - 8.940
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
Via ACCESS Newswire
News headline image
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives 
From Medicus Pharma Ltd
Via GlobeNewswire

Performance

YTD
-82.8%
-82.8%
1 Month
-20.1%
-20.1%
3 Month
-75.0%
-75.0%
6 Month
-88.1%
-88.1%
1 Year
-96.5%
-96.5%

More News

Read More
News headline image
New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN)
Via ACCESS Newswire
News headline image
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
Via ACCESS Newswire
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
Via ACCESS Newswire
News headline image
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
Via ACCESS Newswire
News headline image
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
Via ACCESS Newswire
News headline image
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
Via ACCESS Newswire
News headline image
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
From Medicus Pharma Ltd
Via GlobeNewswire
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026
Via AB Newswire
News headline image
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Via ACCESS Newswire
News headline image
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
Via ACCESS Newswire
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Via ACCESS Newswire
These stocks are making the most noise in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?
Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.
What exchange does Medicus Pharma Ltd. - Common Stock trade on?
Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?
The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market
What is the current price of Medicus Pharma Ltd. - Common Stock?
The current price of Medicus Pharma Ltd. - Common Stock is 0.2748
When was Medicus Pharma Ltd. - Common Stock last traded?
The last trade of Medicus Pharma Ltd. - Common Stock was at 05/19/26 02:22 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today